Ying Gong

Ying Gong has extensive work experience in various roles and positions. Currently, Ying is the Chief Business Officer at GV20 Therapeutics, a position held since April 2022. Prior to that, Ying worked at Genentech from 2012 to 2022, where they held multiple roles including Project Team Leader, Senior Director of Portfolio Strategy and Planning, and Medical Affairs, Program Management, and Business Operations. Before Genentech, Ying worked at Roche from 2009 to 2012 in a role focusing on Global Product Strategy. The earliest work experience recorded is at Bain & Company from 2004 to 2007, where Ying worked as a Consultant. Additionally, Ying worked at Genentech from 2007 to 2009 in a role centered on Market Analysis and Strategy.

Ying Gong has a PhD in Biochemistry and Molecular Biophysics from Caltech. It is unclear when Ying attended Caltech. Ying Gong also studied Genetics and Cell Biology at Peking University, but the details of this education, such as the degree earned and the duration of study, are unknown. Additionally, Ying Gong has an undisclosed educational experience at Smith College.